Cardiovascular Disease

Business

Blue Owl Capital Navigates Legal Storm: Liquidity Lawsuits Clash with Analyst Confidence

Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Business

Argenx's Vyvgart Surges Past Sales Forecasts, Fueling Optimism for Autoimmune Portfolio

Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Business

Trump Poised to Name Kevin Warsh as Next Fed Chair, Setting Stage for Monetary Policy Shift

President Trump is expected to nominate former Fed governor Kevin Warsh as the next Federal Reserve Chair, a move that could signal a pivot toward aggressive rate cuts paired with a reduction of the central bank's balance sheet, reshaping the landscape for markets and cryptocurrencies.

Business

AstraZeneca Bets $1.2 Billion on CSPC's Weight-Loss Drug Pipeline in Major China Deal

British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.

Business

Regeneron's Stock Slump: A Buying Opportunity or a Sign of Deeper Trouble?

Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.

Business

Insmed's Pivotal Moment: Upcoming TPIP Data and Analyst Spotlight Set Stage for Critical Investor Decisions

As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.